John Baldoni is senior vice president of Platform Technology and Science at GSK Pharma R&D. PTS spans the entire spectrum of drug discovery and development, contributing to target characterization and pre-candidate selection through commercial launch and life-cycle management of marketed medicines. Working in partnership with pipeline owners, PTS conducts a range of major activities, including provision of materials and knowledge needed to test the potential of a molecule in early drug discovery; assessment of risks associated with candidate molecules using in vitro and non-clinical models; and provision of the chemistry, formulation, and manufacture of the physical drug product for global manufacturing and supply. These accountabilities cover the pharmaceutical pipeline of small molecules, biopharmaceuticals, and cell and gene therapies. In addition to these activities, PTS is a key contributor to the modernization of R&D.